MPH 510 Module 5 Evaluating a Screening Program Example

Finding Cancer Early Without Doing Harm: Evaluating Low-Dose CT Screening for Lung Cancer

Student Name

Master of Public Health Program, Aspen University

MPH 510: Epidemiology in Public Health

Instructor Name

Month Day, Year

Finding Cancer Early Without Doing Harm: Evaluating Low-Dose CT Screening for Lung Cancer

Screening tests people without symptoms to find disease early, when treatment may work better. But screening also carries harms: false alarms, invasive follow-up tests and the diagnosis of cancers that would never have caused illness. Epidemiology provides the tools to weigh these benefits and harms. This paper evaluates low-dose computed tomography screening for lung cancer, the leading cause of cancer death in the United States.

Criteria for a Good Screening Program

Classic principles hold that the condition should be an important health problem with a detectable early stage, that an acceptable and accurate test should exist, that early treatment should improve outcomes and that the benefits should outweigh the harms and costs. Lung cancer meets the first criterion clearly; the question for decades was whether any test could meet the others.

The Trial

The National Lung Screening Trial randomly assigned 53,454 people at high risk, aged 55 to 74 with at least 30 pack-years of smoking, to three annual screens with low-dose CT or chest radiography. Lung cancer deaths were 247 per 100,000 person-years in the CT group and 309 in the radiography group, a relative reduction of 20.0%, and deaths from any cause fell by 6.7% (National Lung Screening Trial Research Team, 2011).

Test Accuracy Measures

Sensitivity measures how many true cases the test catches; specificity measures how many disease-free people it correctly clears. Predictive values depend on how common the disease is. Positive predictive value asks: of everyone flagged by the test, what fraction really has the disease? The table works through a composite screening round.

False Positives

In the trial, 24.2% of CT screens were positive, and 96.4% of those positive results were false positives (National Lung Screening Trial Research Team, 2011). Most false positives were resolved with follow-up imaging, but some led to biopsies or surgery. The composite table shows why: even a sensitive test yields mostly false positives when fewer than 1 in 100 people screened has the disease.

Overdiagnosis

Overdiagnosis is the detection of a cancer that would never have caused symptoms or death in the person's lifetime. An analysis of the trial's long-term data estimated that 18.5% of lung cancers found by low-dose CT were overdiagnosed, with much higher rates for slow-growing subtypes (Patz et al., 2014). Overdiagnosed patients bear the costs and risks of treatment without benefit.

Lead-Time and Length Bias

Screening can appear to lengthen survival even when it does not. Lead-time bias occurs because diagnosis is simply moved earlier, so survival from diagnosis lengthens even if death occurs at the same time. Length bias occurs because screening preferentially finds slow-growing tumors. For this reason, trials compare death rates between randomized groups rather than survival times, as the lung screening trial did.

Current Recommendation

Drawing on the trial and later evidence and modeling, the US Preventive Services Task Force recommends yearly low-dose CT for adults between 50 and 80 years old who have smoked at least 20 pack-years and still smoke or stopped within the last 15 years (US Preventive Services Task Force, 2021). Lowering the age and pack-year thresholds expanded eligibility, including to more women and Black adults, who tend to develop lung cancer at lower smoking levels.

Uptake and Equity

Despite the recommendation, only a minority of eligible adults are screened. Barriers include limited awareness among patients and clinicians, the requirement for shared decision-making visits, distance to screening centers and cost concerns. Rural residents and people without regular primary care are least likely to be screened, even though smoking rates are often higher among them.

Considerations for a Health Department

A health department promoting screening should target eligible adults, not the general public; pair screening with smoking cessation services; ensure that screening sites use standardized reporting to reduce unnecessary follow-up; support shared decision-making materials that explain false positives and overdiagnosis honestly; and track outcomes, including follow-up procedures and complications.

Weighing Benefits and Harms

For people at high risk, the evidence shows a meaningful reduction in lung cancer deaths. For people at lower risk, the balance shifts, because the number who benefit shrinks while false positives and overdiagnosis remain. This is why eligibility criteria matter and why screening is recommended only for defined high-risk groups.

Why Predictive Value Varies

Predictive values change with prevalence even when sensitivity and specificity stay fixed. If the same test were used in a population in which 5% had cancer rather than 1%, the positive predictive value would rise several-fold. This is why screening is targeted to high-risk groups: concentrating testing where disease is more common means more of the positive findings turn out to be real cancers.

Structured Reporting

After the trial, radiology groups developed structured reporting systems that set size thresholds and follow-up intervals for nodules. Using these systems in practice has reduced the proportion of positive screens compared with the trial, because many small nodules are now followed with repeat imaging rather than classified as positive. Standard reporting also makes results comparable across sites.

Smoking Cessation as Part of Screening

Screening visits are an opportunity to help people quit, which offers a larger health benefit than screening itself. Programs that link screening with cessation counseling and medication address the underlying cause of the disease being screened for. Health departments can support this by connecting screening centers with the state quitline.

Measuring Harms in Programs

Screening programs should record the number of people screened, the share with positive results, follow-up procedures performed, complications and cancers found by stage. These measures show whether a local program achieves a favorable balance similar to the trial or produces more harm through overuse of invasive follow-up.

Conclusion

Low-dose CT screening meets the main criteria for a worthwhile program in high-risk adults, reducing lung cancer deaths by about a fifth in a large randomized trial. Its harms, frequent false positives and overdiagnosis, are real and must be explained to patients. Epidemiological measures of accuracy, awareness of screening biases and attention to equity allow public health professionals to promote screening responsibly.

References

National Lung Screening Trial Research Team. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. New England Journal of Medicine, 365(5), 395-409. https://doi.org/10.1056/NEJMoa1102873

Patz, E. F., Pinsky, P., Gatsonis, C., Sicks, J. D., Kramer, B. S., Tammemägi, M. C., Chiles, C., Black, W. C., & Aberle, D. R. (2014). Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Internal Medicine, 174(2), 269-274. https://doi.org/10.1001/jamainternmed.2013.12738

US Preventive Services Task Force. (2021). Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA, 325(10), 962-970. https://doi.org/10.1001/jama.2021.1117